Marginal Zone Lymphoma
Conditions
Keywords
Obinutuzumab, Lenalidomide
Brief summary
This is a prospective, multicenter clinical study that will enroll 59 patients with relapsed and refractory (R/R) MZL. The study is designed to evaluate the efficacy and safety of the combination of obinutuzumab and lenalidomide in the treatment of relapsed and refractory marginal zone lymphoma (MZL).
Detailed description
Marginal zone lymphoma (MZL) is incurable, and the vast majority of patients with MZL eventually face disease relapse or progression. There is no standard second-line treatment for relapsed/refractory MZL, and the synergistic effect of obinutuzumab and lenalidomide has been demonstrated in other indolent lymphomas. The aim of this trial is to investigate the efficacy and safety of the combination of obinutuzumab (GA101) and lenalidomide in the treatment of R/R marginal zone lymphoma in order to find a safe and effective option for this type of disease.
Interventions
DRUGObinutuzumab
Induction (6 cycles, every 28 days/cycle): 1000 mg each time, administered on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 ( 8 total infusions)； Maintenance(12 cycles, every 2 months/cycle): 12 infusions of 1000 mg every 2 months for 2 years or until disease progression
DRUGlenalidomide
Induction( 6 cycles, every 28 days/cycle): 20 mg/day, oral, Dosing on Days 2-22, every 28 days/cycle of Cycles 1-6； Maintenance(12 cycles, every 28 days/cycle):10 mg on Days 2-22 of each 28-day cycle, 12 cycles for 1 year or until disease progression
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed Informed Consent Form 2. Age ≥18 years 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 4. Histologically confirmed MZL. have a definite diagnosis of MZL 5. Prior treatment with at least one line of systemic lymphoma including prior immunotherapy or chemoimmunotherapy 6. At least one bi-dimensionally measurable nodal lesion (\> 1.5 cm in greatest diameter on CT scan or MRI) OR at least one bi-dimensionally measurable extranodal lesion (\> 1.0 cm in greatest diameter on CT scan or MRI) 7. Need for systemic therapy as assessed by the investigator 8. Life expectancy ≥ 3 months 9. Adequate blood function (except for abnormalities considered by the investigator to be due to the underlying disease of lymphoma), defined as follows: Hemoglobin ≥ 7 g/dL; Absolute neutrophil count ≥ 1.0 × 109/L; Platelet count ≥ 50 x 109/L 10. Normal laboratory values: Creatinine clearance ≥ 30 mL/min; Glutathione transaminase(AST) or glutathione aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN); Serum bilirubin ≤ 2 × ULN (≤ 3 × ULN in patients with Gilbert's syndrome) 11. For men who are not surgically sterile: Agree to use barrier contraception during treatment and for at least 3 months after the last dose of obinutuzumab or lenalidomide or as required by institutional guidelines, whichever is longer. In addition, male patients must agree to have their partner use an alternative method of contraception (e.g., oral contraceptive, intrauterine device, barrier method, or spermicide) 12. For women who are not surgically sterile: use two appropriate methods of contraception, such as oral contraceptives, intrauterine device, or barrier methods, in combination with spermicide for at least 28 days prior to agreeing to start of study medication, during treatment and for at least 12 months after the last dose of either obinutuzumab or lenalidomide, or as required by institutional guidelines, whichever is longer -
Exclusion criteria
1. Patients who are refractory or resistant to lenalidomide or obinutuzumab, refractory is defined as no response (PR or CR) after the start of treatment, or relapse within 6 months (≤ 2 cycles of prior lenalidomide or obinutuzumab and no exclusion of treatment change for non-refractory reasons) 2. History of serious allergic or anaphylactic reactions to monoclonal antibody therapy 3. Known hypersensitivity to any of the study drugs 4. Known sensitivity to murine products 5. Previous ≥ Grade 3 allergic reactions/Hypersensitivity to thalidomide 6. History of erythema multiforme, Grade 3 rash, or blisters following prior immunomodulatory derivative therapy 7. Histologically transformed, highly malignant or diffuse large B-cell lymphoma 8. Central nervous system or meningeal involvement by lymphoma 9. Contraindications for the investigational medical product included in the study treatment regimen 10. Positive test for chronic hepatitis B infection (defined as positive HBsAg serology) 11. Hepatitis C positive (hepatitis C virus antibody serology) 12. HIV or Human T-Lymphocytic Leukemia Virus 1 (HTLV1) positive 13. Evidence of any serious, uncontrolled co-morbidities that affect compliance with the protocol or interpretation of results, including but not limited to significant cardiovascular disease (e.g., New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmias, or unstable angina), or significant pulmonary disease (including history of obstructive pulmonary disease or bronchospasm) 14. Infection caused by known active bacteria, viruses, fungi, or other microorganisms (other than fungal infection of the nail bed), or any major infection requiring intravenous antibiotics or hospitalization (completion of the entire course of antibiotics, except for neoplastic fever) within 4 weeks prior to enrollment 15. Prior malignancy other than lymphoma, unless the subject has a disease-free survival of ≥ 5 years 16. Pregnant or lactating women. 17. Have ≥ Grade 2 neuropathy 18. Participation in another clinical trial using a pharmacological intervention during the trial or within 28 days prior to Cycle 1 19. Corticosteroids within 4 weeks of enrollment, unless administered at a dose equivalent to ≤ 30 mg/day prednisone (within 4 weeks) 20. Past history of progressive multifocal leukoencephalopathy (PML) 21. Live vaccines within 28 days of treatment start 22. History of solid organ transplantation 23. Presence of any serious illness or abnormality in the clinical laboratory test results that, in the opinion of the investigator, would make the patient unable to safely participate and complete this study, or affect protocol compliance or interpretation of results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Remission Rate(ORR) | 24 weeks | Disease response evaluation after 6 cycles will be used to determine the overall remission rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 2-year Progression Free Survival (PFS24): | up to 4.5 years | Progression free survival is defined as the time from the day in which the patient is enrolled to the date on which tumor progresses or the date on which the patient dies for any cause. Responding patients and patients who are lost to follow up will be censored at their last tumor assessment date. |
| 2-year Event-Free Survival (EFS24) | up to 4.5 years | Event-Free Survival will be measured from the date of inclusion to the date of first documented disease progression, relapse, initiation of new anti-lymphoma therapy or death from any cause. |
| Complete Response Rate (CR) | 24 weeks | Disease response evaluation after 6 cycles will be used to determine the overall remission rate |
| Overall survival (OS) | up to 4.5 years | Overall survival will be measured from the date of inclusion to the date of death from any cause. Alive patients will be censored at their last date known to be alive |
Countries
China
Contacts
Primary Contactshuhua Yi, Dr
Backup ContactLugui Qiu, Dr
Outcome results
None listed